Mumps Vaccine (MumpsVax) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high incidence of mumps outbreaks, introduction of routine childhood immunization, effectiveness of live attenuated vaccines, public health vaccination mandates, decline in disease burden after vaccination.

The growth in the forecast period can be attributed to need to prevent re-emerging outbreaks, strengthening of school immunization policies, expansion of global vaccination coverage, focus on herd immunity maintenance, public health surveillance improvements. Major trends in the forecast period include sustained demand for combination vaccines, focus on pediatric immunization programs, continued use in outbreak control strategies, integration with national immunization schedules, emphasis on long-term population immunity.

The rising prevalence of infectious diseases is expected to drive the growth of the mumps vaccine (Mumpsvax) market in the coming years. Infectious diseases are illnesses caused by pathogenic microorganisms, including viruses, bacteria, fungi, or parasites, which can be transmitted between individuals or through contaminated environments. The growing prevalence of infectious diseases is largely influenced by factors such as urbanization, climate change, globalization, and shifts in human demographics and behavior, all of which facilitate the spread and emergence of pathogens. Mumpsvax, a vaccine for mumps, is primarily used to prevent infection from the mumps virus and is often included in the MMR (measles, mumps, rubella) vaccination. For example, in August 2024, the UK Health Security Agency, a UK government agency, reported that in 2023, the West Midlands recorded the highest number of measles cases with 160 cases (44%), followed by London with 122 cases (33%). Children under the age of 10 accounted for 63% of total cases, totaling 232 cases. Measles activity rose significantly toward the end of the year, with 157 new cases in December compared to 45 cases in November. Therefore, the increasing prevalence of infectious diseases is driving the Mumpsvax market.

The growing number of clinical trials is also expected to support the expansion of the mumps vaccine (Mumpsvax) market. Clinical trials are essential for advancing the understanding and treatment of various conditions, including viral infections. Mumpsvax provides targeted immunity against the mumps virus, enabling clinical trials to assess vaccine efficacy, safety, and immune response, particularly in studies focusing on pediatric immunization strategies. For instance, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported that the total number of clinical trials initiated in the UK increased from 411 in 2022 to 426 in 2023. Consequently, the rising number of clinical trials is driving the Mumpsvax market.

Increasing healthcare expenditure is expected to further propel the growth of the mumps vaccine (Mumpsvax) market. Healthcare expenditure encompasses the total funds spent on healthcare goods and services, including personal care, preventive services, and public health initiatives, aimed at improving health outcomes over a given period. The growth in healthcare spending is driven by an aging population, prevalence of chronic diseases, advancements in medical technology, high drug prices, inefficient payment models, and rising demand for healthcare services. Higher healthcare expenditure enhances access to Mumpsvax by funding vaccination programs, which increases immunization rates and improves public health outcomes. For example, in May 2024, the Office for National Statistics, a UK government agency, reported that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to 0.9% growth in 2022. Additionally, long-term health and social care expenditure rose by 2.8% in real terms in 2022. Therefore, rising healthcare spending is driving the Mumpsvax market.

Major companies operating in the mumps vaccine (mumpsvax) market are Merck & Co. Inc., GlaxoSmithKline plc.

North America was the largest region in the mumps vaccine (mumpsvax) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mumps vaccine (mumpsvax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mumps vaccine (mumpsvax) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the mumps vaccine market by influencing the cost of imported vaccine components, packaging materials, and cold-chain logistics. These impacts are most visible in government procurement and hospital pharmacy segments that depend on international suppliers. Regions such as asia-pacific and africa experience higher sensitivity due to reliance on imported combination vaccines. At the same time, tariffs have encouraged domestic vaccine fill-finish operations, improved local supply resilience, and supported long-term immunization security.

The mumps vaccine (mumpsvax) market research report is one of a series of new reports that provides mumps vaccine (mumpsvax) market statistics, including mumps vaccine (mumpsvax) industry global market size, regional shares, competitors with a mumps vaccine (mumpsvax) market share, detailed mumps vaccine (mumpsvax) market segments, market trends and opportunities, and any further data you may need to thrive in the mumps vaccine (mumpsvax) industry. This mumps vaccine (mumpsvax) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mumps vaccine (MumpsVax) is a live attenuated vaccine that protects against mumps using the Jeryl Lynn strain of the virus. It is administered in two doses and is often combined with the MMR (measles, mumps, rubella) vaccine, providing over 95% protection against mumps. Although standalone production has stopped, MumpsVax remains essential for public health efforts to reduce mumps outbreaks and has significantly decreased incidence rates in vaccinated populations.

The main forms of MumpsVax include monovalent, combinational, divalent, trivalent, and others. Monovalent vaccines target only mumps, while combinational vaccines protect against multiple diseases, such as measles and rubella, in a single injection. The vaccine is intended for pediatric and adult age groups and is distributed through hospital pharmacies, drug stores, and retail pharmacies. End-users include pediatric clinics, hospitals, non-governmental organizations (NGOs), and other healthcare providers.

The mumps vaccine (mumpsvax) market consists of sales of mumps vaccines, including both standalone mumps vaccines and combination vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.